Takahiro Yasui Selected Research

Docetaxel (Taxotere)

1/2022	Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
1/2020	Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital.
1/2018	Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis.
11/2017	Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer.
1/2014	Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
6/2013	Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takahiro Yasui Research Topics

Disease

40	Neoplasms (Cancer) 04/2024 - 01/2008
29	Prostatic Neoplasms (Prostate Cancer) 05/2024 - 03/2008
28	Kidney Calculi (Kidney Stone) 04/2024 - 04/2007
26	Carcinoma (Carcinomatosis) 04/2024 - 08/2007
15	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 08/2007
14	Urolithiasis 01/2022 - 06/2004
13	Neoplasm Metastasis (Metastasis) 01/2023 - 06/2013
10	Urinary Calculi (Urinary Calculus) 09/2023 - 02/2002
9	Infections 02/2023 - 11/2008
9	Calculi (Calculus) 01/2022 - 02/2007
9	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 10/2004
9	Inflammation (Inflammations) 05/2019 - 12/2010
6	Shock 09/2023 - 01/2009
6	Hydronephrosis 03/2023 - 07/2007
6	Urinary Tract Infections (Urinary Tract Infection) 03/2022 - 08/2012
5	Nephrolithiasis 03/2024 - 01/2005
5	Adenocarcinoma 11/2022 - 07/2014
5	Ureteral Calculi 09/2022 - 09/2011
5	Bone Resorption 01/2022 - 06/2004
4	Lymphatic Metastasis 07/2022 - 05/2016
4	Osteoporosis 10/2020 - 01/2009
3	Pathologic Constriction (Stenosis) 12/2023 - 05/2020
3	Overactive Urinary Bladder (Overactive Bladder) 10/2023 - 01/2018
3	Hyperthermia 02/2023 - 01/2014
3	Margins of Excision 12/2021 - 08/2013
3	Renal Insufficiency (Renal Failure) 01/2020 - 04/2010
3	Hemorrhage 11/2017 - 02/2014
3	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2017 - 01/2007
3	Seminoma 05/2016 - 01/2007
2	Signet Ring Cell Carcinoma 03/2024 - 01/2013
2	Prolapse 01/2023 - 05/2021
2	Infarction (Infarctions) 01/2023 - 07/2012
2	Pain (Aches) 09/2022 - 01/2017
2	Hematuria 09/2022 - 11/2019
2	Cryptorchidism (Undescended Testes) 03/2022 - 12/2017

Drug/Important Bio-Agent (IBA)

15	Calcium OxalateIBA 04/2024 - 01/2005
13	CalciumIBA 01/2022 - 02/2002
10	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 01/2013
8	NivolumabIBA 04/2024 - 04/2020
8	Gemcitabine FDA Link 01/2022 - 01/2014
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2013
7	AndrogensIBA 05/2024 - 03/2018
6	Androgen Receptors (Androgen Receptor)IBA 05/2024 - 05/2016
6	Biomarkers (Surrogate Marker)IBA 04/2024 - 08/2013
6	Docetaxel (Taxotere)FDA Link 01/2022 - 06/2013
6	MineralsIBA 01/2021 - 07/2008
6	OsteopontinIBA 01/2021 - 06/2004
5	Diphosphonates (Bisphosphonates)IBA 01/2022 - 06/2004
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 08/2007
5	calcium phosphateIBA 01/2022 - 06/2004
5	Ethylene Glycol (Monoethylene Glycol)IBA 01/2016 - 04/2007
4	C-Reactive ProteinIBA 04/2024 - 01/2021
4	pembrolizumabIBA 01/2024 - 01/2020
4	IpilimumabIBA 10/2023 - 04/2020
4	Indicators and Reagents (Reagents)IBA 01/2023 - 10/2019
4	Uric Acid (Urate)IBA 01/2022 - 11/2008
4	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 01/2014
4	melamineIBA 02/2014 - 04/2010
3	Hormones (Hormone)IBA 11/2023 - 03/2022
3	Carboplatin (JM8)FDA LinkGeneric 07/2022 - 05/2017
3	OxalatesIBA 01/2022 - 01/2010
3	Alendronate (Alendronate Sodium)FDA LinkGeneric 01/2022 - 06/2004
3	glyoxylic acid (glyoxylate)IBA 01/2020 - 04/2007
3	cabazitaxel FDA Link 01/2020 - 06/2019
3	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2016
3	Matrix Gla ProteinIBA 01/2013 - 06/2007
2	Immune Checkpoint InhibitorsIBA 04/2024 - 04/2020
2	enfortumab vedotinIBA 04/2024 - 03/2024
2	PlatinumIBA 04/2024 - 01/2014
2	B7-H1 AntigenIBA 04/2024 - 09/2015
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 02/2023 - 03/2022
2	Hemoglobins (Hemoglobin)IBA 01/2023 - 03/2022
2	Paclitaxel (Taxol)FDA LinkGeneric 07/2022 - 11/2017

Therapy/Procedure

37	Therapeutics 05/2024 - 01/2008
24	Drug Therapy (Chemotherapy) 01/2023 - 01/2007
12	Castration 05/2024 - 03/2018
12	Lithotripsy (Extracorporeal Shockwave Lithotripsy) 04/2024 - 01/2009
12	Prostatectomy (Retropubic Prostatectomy) 03/2024 - 03/2008
8	Cystectomy 03/2024 - 01/2013
8	Nephrectomy 10/2022 - 07/2007
7	Operative Time 11/2021 - 08/2012
6	Radiotherapy 03/2024 - 03/2008
5	Orchiectomy (Orchidectomy) 01/2023 - 01/2007
5	Replantation 01/2023 - 08/2012
5	Aftercare (After-Treatment) 01/2023 - 01/2007
4	Stents 09/2023 - 04/2014
4	Punctures 01/2021 - 01/2009
4	Percutaneous Nephrolithotomy 01/2020 - 01/2014
4	Nephroureterectomy 12/2018 - 08/2007
3	Urinary Diversion (Ileal Conduit) 03/2024 - 11/2018
3	Conservative Treatment 01/2023 - 11/2019
3	Adrenalectomy 11/2022 - 07/2014
3	Immunotherapy 10/2022 - 09/2015
3	Combination Drug Therapy (Combination Chemotherapy) 07/2022 - 09/2017
3	Transurethral Resection of Bladder 04/2021 - 09/2015
3	Molecular Targeted Therapy 01/2021 - 08/2020
3	Bed Rest (Bedrest) 12/2012 - 07/2008
2	Lasers (Laser) 12/2023 - 05/2020
2	Length of Stay 09/2023 - 04/2018
2	Minimally Invasive Surgical Procedures 02/2023 - 01/2022